2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia.
Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia (AML).
There are 2 major groups of ways to monitor patients with AML beyond the light microscope, says Stone. The first technique is multiparameter flow cytometry, and the second is based on the mutations in the leukemic cells or specific expression patterns that are present.
Related Content: